Back to News
Market Impact: 0.2
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
Source: GlobeNewswire
Healthcare & BiotechCapital Returns (Dividends / Buybacks)
Clene Inc. closed a registered direct common-stock offering to existing shareholders, including insiders, raising $4 million in gross proceeds. The financing provides incremental capital for the clinical-stage ALS-focused biotechnology company but may dilute existing shareholders.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
CLNN0.15
More News
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Michael Saylor’s Strategy buys Bitcoin again as surprise rally pushes price above $85,000
- Ra Capital Management sells $21.8m in Sionna Therapeutics shares
- Why is Labcorp stock sliding today?
- Why is Quest Diagnostics stock sliding today?